Ditumopa, Rudy D.
HRN: 20-19-46 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/13/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/13/2023
12/19/2023
IV
2.25g
Q8
CAP-MR; Infected Wound
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes